Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
News18 English
News18 » Business
1-min read

Novartis stock down 4.5 per cent after SC verdict

Shares of drug companies Cipla, Dr Reddy's, Ranbaxy, Glenmark and Aurobindo Pharma were up between 2 to 5 per cent.

CNN-IBN

Updated:April 1, 2013, 11:48 AM IST
facebookTwitterskypewhatsapp
Novartis stock down 4.5 per cent after SC verdict
Shares of drug companies Cipla, Dr Reddy's, Ranbaxy, Glenmark and Aurobindo Pharma were up between 2 to 5 per cent.
Loading...

Mumbai: Shares of the Swiss pharmaceutical giant Novartis fell about 4.5 per cent on Monday after the Supreme Court of India dismissed its plea for a patent on its cancer drug, Gelvic. Shares of select Indian pharmaceutical companies rallied as the industry is set to receive a boost following the verdict.

Brokers say the market is betting more local pharma companies will be encouraged to come out with the copycat generic versions of life-saving drugs. The Supreme Court upheld an earlier verdict by the tribunal and patent body and said that Glivec failed the test for innovation as specified under the Patent Act.

Shares of drug companies Cipla, Dr Reddy's, Ranbaxy, Glenmark and Aurobindo Pharma were up between 2 to 5 per cent. Indian drug companies can now roll out a generic version of the drug, which can cost about Rs 10,000 a month - slashing the price by almost 92 per cent. Currently priced at Rs 1.2 lakh for a monthly dosage, Glivec is a major advance in treating chronic myeloid leukaemia, which kills 80-90 per cent of sufferers, and some gastrointestinal cancers.

(With Additional Inputs From moneycontrol.com)

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

Subscribe to Moneycontrol Pro and gain access to curated markets data, trading recommendations, equity analysis, investment ideas, insights from market gurus and much more. Get Moneycontrol PRO for 1 year at price of 3 months. Use code FREEDOM.

Read full article
Loading...
Next Story
Next Story

Also Watch

facebookTwitterskypewhatsapp
Most Active
Company Price Change %Gain
Yes Bank 59.25 5.24
Indiabulls Hsg 467.85 3.84
Reliance 1,275.85 2.33
HDFC Bank 2,162.70 -0.52
ICICI Bank 395.40 -0.93
Company Price Change %Gain
Yes Bank 59.25 5.24
ICICI Bank 395.75 -0.85
Indiabulls Hsg 467.90 4.00
Bajaj Finance 3,175.35 1.85
Reliance 1,275.95 2.36
Top Gainers
Company Price Change %Gain
Zee Entertain 351.15 6.75
Vedanta 137.40 6.47
UPL 547.25 5.64
Yes Bank 59.25 5.24
BPCL 329.35 5.22
Company Price Change %Gain
Vedanta 137.50 6.55
Yes Bank 59.25 5.24
ONGC 122.30 4.66
M&M 533.10 4.09
Coal India 188.05 4.07
Top Losers
Company Price Change %Gain
IndusInd Bank 1,310.50 -1.88
ITC 236.10 -1.65
ICICI Bank 395.40 -0.93
Eicher Motors 15,383.45 -0.90
HUL 1,860.00 -0.65
Company Price Change %Gain
IndusInd Bank 1,310.35 -1.90
ITC 236.00 -1.71
ICICI Bank 395.75 -0.85
Power Grid Corp 201.40 -0.69
HUL 1,859.35 -0.69

Live TV

Loading...
Countdown To Elections Results
To Assembly Elections 2018 Results